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SUMMARY
Mycophenolate mofetil (MMF) rapidly substituted azathioprine (AZA) in transplant immunosup-
pression regimens during the 1990s, when early clinical trials indicated better outcomes. However, 
none of these trials used the well-established optimization methods for AZA dosing: thiopurine 
methyltransferase (TPMT) pharmacogenetics combined with monitoring of thioguanine nucleo-
tides (TGN). This reticence to optimize AZA therapy continues today in transplant therapy, despite 
the fact that TPMT and TGN testing are being widely used by other medical disciplines. The advent 
of co-therapy with calcineurin inhibitors, such as tacrolimus, negated any advantages of MMF over 
AZA; in fact, both rejection rates and graft survival are better with AZA. Yet, despite its inferior 
performance and far higher cost, MMF continues to be used in preference to AZA. The experience 
of the Renal Transplant Unit of Hospital das Clínicas in São Paulo, Brazil, provides an example of 
how AZA therapy can be optimized, using TPMT to predict initial AZA dose, then TGN monitor-
ing to guide dose adjustments. Future trends in transplant immunosuppression are discussed; in 
particular the success of AZA co-therapy with allopurinol, a drug which was designed specifically 
to improve thiopurine response. “Biological” antibody-based immunosuppressants may have a role 
in acute rejection episodes, although graft survival does not appear to be enhanced. These drugs 
are also limited by development of patient resistance and very high cost. The future of immunosup-
pression thus surprisingly seems tied to thiopurines such as AZA, with optimization of their use 
being the key to success.
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RESUMO
O micofenolato substituiu a azatioprina em esquemas de  
imunossupressão. Mas ele é melhor?
O micofenolato mofetil (MMF) substituiu rapidamente a azatioprina (AZA) na imunossupressão 
em transplante durante os anos 1990, quando os primeiros ensaios clínicos indicaram melhores 
resultados. No entanto, nenhum destes ensaios utilizou os bem estabelecidos métodos para a oti-
mização das dosagens de AZA: farmacogenética da tiopurina metiltransferase (TPMT) combinada 
à monitorização dos nucleotídeos de tioguanina (TGN). Essa reticência em aperfeiçoar a terapia 
com AZA persiste ainda hoje na terapia de transplantes, apesar de os testes da TPMT e da TGN 
serem amplamente utilizados por outras disciplinas médicas, como a gastroenterologia. O advento 
da coterapia com inibidores da calcineurina, como tacrolimus, negou qualquer vantagem do MMF 
sobre AZA, na verdade, ambas as taxas de rejeição e sobrevida do enxerto são melhores com a 
AZA. No entanto, apesar de seu desempenho inferior e custo muito mais elevado, o MMF continua 
a ser usado em preferência a AZA. A experiência da Unidade de Transplante Renal do Hospital das 
Clínicas de São Paulo, Brasil, fornece um exemplo de como a terapia com AZA pode ser otimizada 
usando-se a TPMT para prever dose inicial de AZA e, em seguida, monitorando o TGN para guiar 
os ajustes de dose. As tendências futuras na imunossupressão do transplante são discutidas, em 
particular o sucesso da coterapia AZA e alopurinol, uma droga que foi projetada especificamente 
para melhorar a resposta às tiopurinas. Imunossupressores baseados em anticorpos biológicos po-
dem ter um papel nos episódios de rejeição aguda, embora a sobrevida do enxerto não pareça ser 
reforçada. Essas drogas também são limitadas pelo desenvolvimento de resistência do paciente e 
pelo custo muito elevado. O futuro da imunossupressão, assim, surpreendentemente parece ligado 
a tiopurinas como a AZA, com o aperfeiçoamento do seu uso sendo a chave para o sucesso.
Unitermos: Azatioprina; micofenolato; transplante renal; eficácia.
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BACKGROUND: AZATHIOPRINE AND MYCOPHENOLATE 
Azathioprine (AZA) was the first successful immunosup-
pressant, and opened the era of organ transplantation. It 
was developed from the earlier invention of the antime-
tabolite mercaptopurine, which had proved to be success-
ful in the treatment of acute lymphoblastic leukemia. The 
lymphoid specificity of the thiopurine group of drugs led 
in the early 1960s to the development of AZA as an immu-
nosuppressant agent specifically for renal transplant, by 
Gertrude Elion and George Hitchings1. Initially, AZA was 
used in combination with prednisolone (double therapy) 
but with the advent of cyclosporine-A (CyA) in the 1970s, 
a ‘triple therapy’ regimen of AZA/Prednisolone (Pred)/ 
CyA became standard for two decades.
The antimetabolite mycophenolic acid was discovered 
as a fermentation product of Penicillium brevicompactum 
in 1893, and the pharmaceutical prodrug formulation my-
cophenolate mofetil (MMF) was approved for clinical use 
as an immunosuppressant in 1995. Since 2002, MMF has 
become the most frequently used immunosuppressant for 
solid organ transplantation, particularly kidney transplan-
tation, with up to 80% of renal transplant patients receiv-
ing MMF in the USA2, despite significant gastrointestinal 
complications, which may lead to MMF dose reductions 
and drug withdrawal. Another prodrug of MPA, enteric-
coated sodium mycophenolate, was approved for trans-
plantation in 2004, but clinical experience with this for-
mulation remains limited.
MMF CLINICAL TRIALS: HIGHER REJECTION AT HIGHER COST
In the mid-1990s, two influential clinical trials with triple 
therapy including MMF/Pred/CyA showed results supe-
rior to AZA/Pred/CyA for renal transplant3,4. At that time, 
most transplant units in the world changed their immu-
nosuppressive regimen to MMF in place of AZA. How-
ever, a new microemulsion form of cyclosporine – Neoral 
– appeared, with improved pharmacokinetics. In a large 
multicenter, prospective, randomized trial by Remuzzi 
et al.5 incorporating Neoral, MMF was compared with 
AZA for acute rejections and adverse events, in recipients 
of cadaver kidney transplants. MMF or AZA treatments 
were run for six months in combination with Neoral-
CyA/Pred (Phase A), and for another 15 months without 
Pred (Phase B). The primary endpoint was occurrence of 
acute rejection episodes. Interestingly, the results showed 
no significant difference in rejection rates for MMF ver-
sus AZA: for Phase A, which included steroid therapy, the 
MMF group exhibited a rejection rate of 56/168 (34%), 
while for the AZA group with steroids the rejection rate 
was 58/168 (35%). For Phase B, without steroids, the dif-
ference between the two drugs became more apparent: the 
rejection rate for MMF co-therapy was 14/88 (16%), while 
for AZA it was considerably lower, 11/89 (12%). Notably, 
the average per-patient costs of MMF treatment signifi-
cantly exceeded that of AZA: for Phase A, MMF/Pred/
Neoral-CyA therapy cost of € 2,665 (SD ± 586) compared 
with AZA/Pred/Neoral-CyA cost of € 184 (± 62). For 
Phase B, the average cost of MMF/Neoral-CyA was € ,095 
(± 2,658) versus the AZA/Neoral-CyA cost of € 322 (± 170) 
(p < 0.0001 for both phases). Therefore it could be con-
cluded that MMF had shown – at best – no advantages 
over AZA in terms of clinical outcome, but the costs were 
greatly increased with MMF.
Shah et al.6 undertook the first analysis comparing the 
effects of Pred/Neoral-CyA with either MMF or AZA on 
the outcomes of paired renal grafts in the United King-
dom. The study included 238 deceased donors from 1999 
to 2002 who donated one kidney to a patient treated with 
MMF and the other kidney to a patient treated with AZA. 
Shah et al. concluded that although other published ran-
domized controlled trials appeared to show that MMF 
reduced acute rejection rates and improved renal graft 
survival, this study had demonstrated no graft survival 
differences between MMF and AZA, and higher rejection 
rates with MMF. A similar superior outcome for AZA over 
MMF was also reported by Shah et al.7 in a retrospective 
study of 10-year renal graft survival.
During 1994, another calcineurin inhibitor – tacrolimus 
(or FK-506) – was licensed for liver transplantation and later 
for other organs and almost displaced CyA from the mar-
ket. Although both are calcineurin inhibitors, tacrolimus 
appears to be clinically more effective; however, there have 
been few differences when side effects are considered: 
among others, both are equally nephrotoxic, and although 
CyA causes more trembling, there is more post-transplant 
diabetes with tacrolimus.
Schold et al.8 assessed graft survival among renal trans-
plant patients receiving Pred/ tacrolimus with either AZA 
or MMF, and found similar outcomes: in fact AZA co-
therapy provided better graft survival and lower rejection 
rates than MMF.
IMPROVING AZATHIOPRINE EFFICACY
TPMT PHARMACOGENETICS
In retrospect, there have been serious deficiencies in virtu-
ally all clinical trials comparing the efficacy of AZA with 
MMF. The absence of initial assessment of thiopurine 
methyltransferase (TPMT) genetic status or therapeutic 
monitoring of thiopurine metabolites have been striking 
oversights. TPMT is a classic pharmacogenetic model for 
predicting drug dosage, and testing (genotype or pheno-
type) has been widely available since the early 1990s. We 
published the first study using TPMT for renal trans-
plantation in 1992, in Brazilian patients receiving AZA 
triple therapy9. Several other early studies confirmed that 
TPMT – combined in some cases with therapeutic drug 
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monitoring – improved the efficacy and safety of AZA in 
organ transplant. Bergan et al.10 used TPMT to predict 
initial dosage, and there have been numerous studies on 
TPMT status to retrospectively explain bone marrow tox-
icity. However, TPMT testing thus continues to be rarely 
used prospectively in transplant therapy, despite having 
become routine for guiding initial thiopurine drug dosage 
in gastroenterology, dermatology and other clinical disci-
plines: for example, a clinical trial in progress during 2011, 
comparing the efficacy of AZA and MMF, has failed to in-
clude assessment of TPMT status11. 
THIOPURINE METABOLITE MONITORING
Therapeutic monitoring of thiopurine metabolites, in par-
ticular levels of 6-thioguanine nucleotide (6-TGN) and 
6-methyl-mercaptopurine (6-MMP), has also become 
routine for a number of medical disciplines that use AZA 
and mercaptopurine. Thiopurine dose adjustment based 
on erythrocyte 6-TGN/6-MMP has been demonstrated to 
reduce the risk of toxicity and improve efficacy of AZA 
immunosuppression. This would be predicted to result 
in improved graft survival with reduced side effects for 
transplant patients.
Bergan et al.12 demonstrated that a triple-drug regi-
men with high-dose AZA, monitored by 6-TGN, facili-
tated the regulation of myelotoxicity within acceptable 
limits with the benefit of a reduction in acute rejection 
episodes.  In 1999, a Polish renal transplant group ana-
lyzed 6-TGN/6-MMP levels in patients with the aim of in-
dividualizing therapy for optimal outcome13. Apart from 
a few reports, prospective metabolite monitoring has also 
been absent from thiopurine transplant therapy: for ex-
ample, the above-mentioned current studies comparing 
MMF versus AZA for kidney transplantation appear to be 
lacking thiopurine TDM4-8.
Can the use of AZA immunosuppression be opti-
mized for organ transplantation? This also raises a sec-
ond important question: Would the optimization of AZA 
therapy increase its efficacy and further extend its superi-
ority over MMF?
THIOPURINE MONITORING FOR KIDNEY TRANSPLANT IN BRAZIL
During 2008, the Central Laboratories, Division of Clini-
cal Biochemistry, Faculdade de Medicina, Universidade 
de São Paulo, established routine monitoring of 6-TGN in 
transplant patients (see Pacheco-Neto et al., in this issue). 
6-TGN monitoring has been found to be clinically useful 
for compliance and for adjusting the therapy. Similar to 
Bergan et al.12, approximately one third of all renal trans-
plant patients at Hospital das Clínicas in São Paulo have 
been found to have 6-TGN levels that were insufficient, 
i.e., < 100 units (pmol/8x108 red blood cells) or undetect-
able, which may be associated with chronic rejection, and 
thus monitoring has facilitated the appropriate adjust-
ment of AZA dosing. Where the patient’s metabolism ap-
pears to be resistant to AZA dose increments, allopurinol 
co-therapy has been used at Hospital das Clínicas. TPMT 
can be used to predict initial AZA dose for each patient, 
and this is particularly important when AZA is used in 
combination with allopurinol (see also Ansari, this issue).
ALLOPURINOL CO-THERAPY
The beneficial effect of allopurinol co-therapy with azathi-
oprine in organ transplant was first demonstrated for renal 
grafts by Chocair et al.14 at Hospital das Clínicas, with 12 
cadaver transplant recipients. The patients received stan-
dard triple therapy of AZA/ Pred/ CyA, but supplemented 
with low-dose allopurinol, and the AZA dose was lowered 
accordingly. Only one episode of rejection was observed 
among the 12 allopurinol-treated patients, whereas 11 of 
12 in a control group had rejection episodes, seven with 
two or more crises. In total, four allopurinol-treated pa-
tients and three controls required further AZA dose re-
duction because of leukopenia. There was no difference in 
infection rates between the two groups.
Chrzanowska & Krzymanski13 compared 21 renal 
transplant patients on AZA triple therapy with six trans-
planted patients on AZA triple therapy plus allopurinol. 
The median AZA dose (mg/d) was considerably lower 
when allopurinol was included: 33 mg AZA (range 25-50) 
versus 68 mg (25-100) for normal triple therapy. On the 
other hand, the median 6-TGN was significantly higher 
for the allopurinol co-therapy group: 363 units (129-623) 
versus 122 units (< 60-288) for normal triple therapy 
(p < 0.005).
The benefits of AZA/allopurinol co-therapy have 
been more recently extended to inflammatory bowel 
disease. Sparrow et al.15 tested patients resistant to AZA 
therapy who tended to ‘shunt’ thiopurines towards the 
methylation pathway (producing 6-MMP) and away 
from 6-TGN. He showed that after starting allopurinol, 
6-TGN levels increased from a mean of 186 (+/-18) to 
385 units (+/-42) (p < 0.001), while 6-methylmercapto-
purine decreased from a mean of 10,380 (+/-1245) to 
1,732 units (+/-502) (p < 0.001). Sparrow concluded that 
“the addition of allopurinol to thiopurine non-respond-
ers with preferential shunting to 6-methylmercaptopu-
rine metabolites appears to be an effective means to shift 
metabolism” (i.e. towards 6-TGN)15.
Ansari et al.16 has recently demonstrated that thera-
py using allopurinol with low dose AZA is an effective 
strategy for overcoming thiopurine hepatotoxicity. In 
particular, Ansari has been the first to show that AZA/
allopurinol co-therapy is safe and effective for long-term 
use, particularly when used with TPMT prediction of ini-
tial dosage, provided that myelotoxicity is monitored17.
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FUTURE THERAPIES
Similar to immunosuppression for auto-immune inflam-
matory diseases such as Crohn’s disease, transplantation 
immunosuppression has also moved towards ‘biologi-
cal’ immunosuppression (i.e. monoclonal antibodies). 
However there are problems. First, the long-term effica-
cy of antibody-based drugs is problematic, as experience 
from their use for inflammatory bowel disease indicates 
that resistance to these drugs develops within a compara-
tively short time (1-2 years). Second, although these new 
immunosuppressive agents can dramatically decrease the 
incidence of rejection, surprisingly, the lower rates of acute 
rejection in clinical trials have not resulted in higher graft 
survival. This may be because antibody-mediated damage, 
not controlled by these new biologicals, is mechanistic in 
long-term graft loss17. In particular, these drugs are also 
limited by very high cost.
CONCLUSIONS
We may conclude therefore that more optimized usage 
of the thiopurine drug AZA would greatly extend its ad-
vantages over MMF in post-transplantation therapy.  Im-
portant aspects for more effective AZA therapy are dose 
prediction using TPMT, followed by thiopurine metabo-
lite monitoring. AZA co-therapy with allopurinol has been 
shown to be beneficial for some patients. Thus, with a 60+ 
year history, AZA has proved to be remarkably resilient. 
With modern adaptations for its use, and its clear cost ad-
vantages for stressed health budgets, its future in immuno-
suppression therapy seems assured.
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